BACKGROUND: Although bullous pemphigoid (BP) is a benign self-limited disease, the mainstay of treatment remains systemic steroids, often in combination with immunosuppressive agents. This therapy has considerable potential toxicity, particularly in elderly patients with preexisting problems. OBJECTIVE: The purpose of this study was to evaluate the efficacy of oral tetracycline as first-choice therapy in patients with BP. METHODS: Every patient newly diagnosed with generalized BP was treated with oral tetracycline and a midpotency topical steroid. RESULTS: In all five patients, blister formation was stopped and reepithelialization completed within 1 to 3 weeks. There was no relapse or toxicity noted; follow-up ranged from 16 to 24 months. CONCLUSION: Oral tetracycline was found to be rapidly efficacious in all patients and devoid of toxicity.
BACKGROUND: Although bullous pemphigoid (BP) is a benign self-limited disease, the mainstay of treatment remains systemic steroids, often in combination with immunosuppressive agents. This therapy has considerable potential toxicity, particularly in elderly patients with preexisting problems. OBJECTIVE: The purpose of this study was to evaluate the efficacy of oral tetracycline as first-choice therapy in patients with BP. METHODS: Every patient newly diagnosed with generalized BP was treated with oral tetracycline and a midpotency topical steroid. RESULTS: In all five patients, blister formation was stopped and reepithelialization completed within 1 to 3 weeks. There was no relapse or toxicity noted; follow-up ranged from 16 to 24 months. CONCLUSION: Oral tetracycline was found to be rapidly efficacious in all patients and devoid of toxicity.
Authors: Kelly N Messingham; Michael P Cahill; Samuel H Kilgore; Ananya Munjal; Patrick M Schlievert; Janet A Fairley Journal: J Invest Dermatol Date: 2021-10-01 Impact factor: 7.590